Extracellular matrix-producing composition using mast4 gene and preparation method therefor

Abstract

The present invention relates to a composition for producing an extracellular matrix from a eukaryotic cell, the composition comprising a polypeptide or compound capable of specifically binding to a microtubule associated serine/threonine kinase family member 4 (MAST4) protein or a fragment thereof or a polynucleotide, polypeptide or compound capable of specifically binding to a nucleic acid coding for the MAST4 protein or a fragment thereof, and a composition for promoting chondrogenesis, comprising the same composition.

1 . A composition for promoting production of an extracellular matrix from eukaryotic cells, the composition comprising a compound capable of specifically binding to Microtubule Associated Serine/Threonine Kinase Family Member 4 (MAST4) protein or a fragment thereof, or a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or the fragment thereof. 
     
     
         2 . The composition of  claim 1 , wherein the MAST4 protein comprises any one amino acid sequence of SEQ ID NOS: 1 to 7 and 15, and the nucleic acid encoding the MAST4 protein comprises any one polynucleotide sequence of SEQ ID NOS: 8 to 14 and 16. 
     
     
         3 . The composition of  claim 1 , wherein the compound capable of specifically binding to the MAST4 protein or the fragment thereof, or the compound capable of specifically binding to the nucleic acid encoding the MAST4 protein or the fragment thereof is a chemically synthesized compound, polypeptide, or polynucleotide that inhibits activity or expression of the MAST4 protein, or a combination thereof. 
     
     
         4 . The composition of  claim 3 , wherein the polypeptide is an antibody or an antigen-binding site thereof. 
     
     
         5 . The composition of  claim 1 , wherein the compound capable of specifically binding to the nucleic acid encoding the MAST4 protein or the fragment thereof is microRNA (miRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), Piwi-interacting RNA (piRNA), small nuclear RNA (snRNA), or antisense oligonucleotide, each specific to the nucleic acid encoding the MAST4 protein or the fragment thereof, or a combination thereof. 
     
     
         6 . The composition of  claim 1 , wherein the compound capable of specifically binding to the nucleic acid encoding the MAST4 protein or the fragment thereof is CRISPR-Cas comprising guide RNA specific to the nucleic acid encoding the MAST4 protein or the fragment thereof. 
     
     
         7 . The composition of  claim 6 , wherein the guide RNA is a dual RNA comprising CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA) specific to the nucleic acid encoding the MAST4 protein or the fragment thereof, or a single strand guide RNA comprising parts of the crRNA and the tracrRNA and hybridizing with the nucleic acid encoding the MAST4 protein or the fragment thereof. 
     
     
         8 . The composition of  claim 1 , wherein the eukaryotic cells are fibroblast cells or chondrocytes. 
     
     
         9 . The composition of  claim 1 , wherein the composition is to promote chondrogenesis of the eukaryotic cells. 
     
     
         10 . The composition of  claim 1 , wherein the composition is to prevent or treat a joint disease or to improve symptoms thereof. 
     
     
         11 . The composition of  claim 9 , wherein to promote chondrogenesis is to induce chondrogenesis. 
     
     
         12 . The composition of  claim 1 , wherein the composition is used for tissue regeneration or anti-aging. 
     
     
         13 . The composition of  claim 1 , further comprising TGF-β1. 
     
     
         14 . A method of preventing, treating, or improving a joint disease, the method comprising administering the composition of  claim 1  to a subject. 
     
     
         15 . A method of producing an extracellular matrix from eukaryotic cells, the method comprising contacting the eukaryotic cells with the composition for promoting production of extracellular matrix from eukaryotic cells of  claim 1 . 
     
     
         16 . The method of  claim 15 , wherein the eukaryotic cells are isolated from a subject. 
     
     
         17 . The method of  claim 15 , wherein the contacting with the eukaryotic cells comprises culturing the eukaryotic cells in the presence of the composition. 
     
     
         18 . The method of  claim 17 , wherein the culturing is to culture in the presence of a chondrogenic inducer. 
     
     
         19 . The method of  claim 15 , further comprising isolating the extracellular matrix from the contacting product. 
     
     
         20 . The method of  claim 15 , wherein the eukaryotic cells are chondrocytes.